Skip to main content

Risk Factors and Biomarkers of RA-ILD

  • Doyle T
  • Dellaripa P
  • Rosas I
Citations of this article
Mendeley users who have this article in their library.
Get full text


Lung disease in rheumatoid arthritis (RA) is one of the leading causes of death in RA patients [1]; interstitial lung disease (ILD) is the most common clinical mani- festation of lung involvement in RA and the only complication of RA increasing in prevalence [2] with substantial risk for progressive morbidity and mortality [3]. Despite this, RA-ILD often goes unrecognized, highlighting the need for improved recognition and management of disease, including identification of targets for dis- ease prevention; clinical tools that classify early stages of disease, such as clinical prediction models; and a personalized approach to diagnosis and treatment. As such, the focus of this chapter will be on risk factors and protein biomarkers of RA-ILD with a brief discussion on other potential molecular and genetic markers extrapolated from ongoing research in idiopathic pulmonary fibrosis (IPF) and other connective tissue disease-ILD (CTD-ILD), such as systemic sclerosis (SSc). RA-ILD




Doyle, T. J., Dellaripa, P. F., & Rosas, I. O. (2018). Risk Factors and Biomarkers of RA-ILD (pp. 59–72).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free